Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Elisabetta Abruzzese

Elisabetta Abruzzese

MD, PhD
S. Eugenio University Hospital
Treatment-free remission in Ph+ ALL without alloSCT: ongoing research 1:48
Treatment-free remission in Ph+ ALL without alloSCT: ongoing research
Elisabetta Abruzzese • 4 Sep 2025
Exploring TKI de-escalation strategies in CML: outcomes of downgrading therapy 1:33
Exploring TKI de-escalation strategies in CML: outcomes of downgrading therapy
Elisabetta Abruzzese • 4 Sep 2025
A CML Campus study assessing the transition from high-potency to low-potency inhibitors in CML 3:51
A CML Campus study assessing the transition from high-potency to low-potency inhibitors in CML
Elisabetta Abruzzese • 6 Dec 2024
The impact of ponatinib on conception and pregnancy outcomes in patients with CML 2:13
The impact of ponatinib on conception and pregnancy outcomes in patients with CML
Elisabetta Abruzzese • 6 Dec 2024
Could asciminib be the new breakthrough in the treatment of CML? 2:42
Could asciminib be the new breakthrough in the treatment of CML?
Elisabetta Abruzzese • 6 Dec 2024
Advancing CML treatment: novel drugs, personalized treatment strategies, and improving TFR 2:09
Advancing CML treatment: novel drugs, personalized treatment strategies, and improving TFR
Elisabetta Abruzzese • 4 Sep 2024
Advice for managing pregnancy in patients with CML 1:03
Advice for managing pregnancy in patients with CML
Elisabetta Abruzzese • 4 Sep 2024
Practical advice for the management of patients with CML who are pregnant or wish to conceive 4:47
Practical advice for the management of patients with CML who are pregnant or wish to conceive
Elisabetta Abruzzese • 4 Sep 2024
Investigating the outcomes of children born to patients with CML 5:18
Investigating the outcomes of children born to patients with CML
Elisabetta Abruzzese • 11 Dec 2023
Patients with Ph+ CML entering TFR in pregnancy: a sub-analysis of the Italy TFR registry 4:32
Patients with Ph+ CML entering TFR in pregnancy: a sub-analysis of the Italy TFR registry
Elisabetta Abruzzese • 11 Dec 2023
Situations that may arise with CML during pregnancy & management strategies 5:35
Situations that may arise with CML during pregnancy & management strategies
Elisabetta Abruzzese • 8 Sep 2023
CML during pregnancy: implications and considerations for treatment 9:13
CML during pregnancy: implications and considerations for treatment
Elisabetta Abruzzese • 8 Sep 2023
The role of JAK inhibitors in treating MPNs and the need for disease-modifying agents 4:42
The role of JAK inhibitors in treating MPNs and the need for disease-modifying agents
Elisabetta Abruzzese • 24 Oct 2022
The value of using personalized approaches when treating patients with MF 1:11
The value of using personalized approaches when treating patients with MF
Elisabetta Abruzzese • 24 Oct 2022
The content of VJHemOnc is intended for healthcare professionals